Moreover, epigalocathechin-3-gallate inhibits activation of the epidermal growth factor receptor in carcinoma cells, and it was proposed that epigalocathechin-3-gallate may be valuable in treating cases of breast carcinoma and human head and neck squamous cell carcinoma in which activation of the EGFR and/or HER-2 plays significant roles in tumor survival and growth [33]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.